bluebird bio (NASDAQ:BLUE) – Investment analysts at Cantor Fitzgerald lifted their FY2018 earnings per share estimates for shares of bluebird bio in a note issued to investors on Tuesday, May 22nd. Cantor Fitzgerald analyst E. Piros now anticipates that the biotechnology company will post earnings of ($10.22) per share for the year, up from their prior estimate of ($10.89). Cantor Fitzgerald has a “Underweight” rating on the stock.
BLUE has been the subject of a number of other research reports. Maxim Group restated a “hold” rating and issued a $200.00 target price on shares of bluebird bio in a research report on Thursday, February 22nd. Canaccord Genuity restated a “buy” rating and issued a $250.00 target price on shares of bluebird bio in a research report on Tuesday, March 13th. Leerink Swann downgraded bluebird bio from an “outperform” rating to a “market perform” rating and boosted their target price for the stock from $162.00 to $194.00 in a research report on Thursday, January 25th. SunTrust Banks boosted their target price on bluebird bio to $232.00 and gave the stock a “buy” rating in a research report on Thursday, April 19th. Finally, Janney Montgomery Scott assumed coverage on bluebird bio in a research report on Wednesday, March 14th. They issued a “neutral” rating and a $220.00 target price for the company. Four analysts have rated the stock with a sell rating, nine have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. bluebird bio has a consensus rating of “Hold” and an average price target of $195.80.
bluebird bio (NASDAQ:BLUE) last released its earnings results on Monday, May 7th. The biotechnology company reported ($2.31) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.01) by ($0.30). The firm had revenue of $15.96 million during the quarter, compared to the consensus estimate of $5.85 million. bluebird bio had a negative return on equity of 27.61% and a negative net margin of 857.55%. The business’s quarterly revenue was up 133.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.68) EPS.
In other news, Director Mark Vachon sold 6,000 shares of the business’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $214.38, for a total transaction of $1,286,280.00. Following the transaction, the director now directly owns 7,000 shares of the company’s stock, valued at $1,500,660. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Philip D. Gregory sold 2,250 shares of the business’s stock in a transaction that occurred on Thursday, March 1st. The shares were sold at an average price of $200.00, for a total value of $450,000.00. Following the transaction, the insider now directly owns 32,522 shares in the company, valued at $6,504,400. The disclosure for this sale can be found here. Insiders sold a total of 46,250 shares of company stock worth $8,269,990 over the last ninety days. Insiders own 3.00% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of BLUE. Two Sigma Advisers LP increased its stake in shares of bluebird bio by 3,004.0% during the fourth quarter. Two Sigma Advisers LP now owns 462,500 shares of the biotechnology company’s stock valued at $82,371,000 after buying an additional 447,600 shares during the period. Redmile Group LLC purchased a new position in shares of bluebird bio during the fourth quarter valued at approximately $46,270,000. BlackRock Inc. increased its stake in shares of bluebird bio by 6.4% during the fourth quarter. BlackRock Inc. now owns 3,831,371 shares of the biotechnology company’s stock valued at $682,366,000 after buying an additional 231,697 shares during the period. Franklin Resources Inc. increased its stake in shares of bluebird bio by 41.3% during the fourth quarter. Franklin Resources Inc. now owns 686,900 shares of the biotechnology company’s stock valued at $122,337,000 after buying an additional 200,900 shares during the period. Finally, Carillon Tower Advisers Inc. purchased a new position in shares of bluebird bio during the fourth quarter valued at approximately $27,213,000.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.